Effect of BIA 5 1058 on Cardiac Repolarization

Phase 1 Completed 49 enrolled Bial - Portela C S.A. Covance · collab

RandomizedCrossoverTriple-blindTreatment

Summary

The purpose is to evaluate the effect of single therapeutic (400 mg) and supratherapeutic (1200 mg) doses of BIA 5-1058 on the time-matched change from baseline in placebo-adjusted interval corrected (QT) for heart rate (HR)

Timeline

Start: 2018-04-09
Primary completion: 2018-10-05
Completion: 2018-10-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Moxifloxacin	Small molecule	400 mg	—
Subject	zamicastat	Small molecule	400 mg	Oral
Subject	zamicastat	Small molecule	1200 mg	Oral

Effect of BIA 5 1058 on Cardiac Repolarization

Summary

Timeline

Drugs

Indications